Get the Stockscreener App
6.29
4.31%
0.26
After Hours:
6.28
-0.010
-0.16%
Eupraxia Pharmaceuticals Inc stock is traded at $6.29, with a volume of 435.30K.
It is up +4.31% in the last 24 hours and down -9.10% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
See More
Previous Close:
$6.03
Open:
$6.01
24h Volume:
435.30K
Relative Volume:
1.99
Market Cap:
$410.91M
Revenue:
-
Net Income/Loss:
$-44.47M
P/E Ratio:
-6.1782
EPS:
-1.0181
Net Cash Flow:
$-33.50M
1W Performance:
+6.25%
1M Performance:
-9.10%
6M Performance:
+0.00%
1Y Performance:
+47.31%
1-Day Range:
$5.95
$6.46
1-Week Range:
$5.63
$6.46
52-Week Range:
$4.19
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.29 | 406.33M | 0 | -44.47M | -33.50M | -1.0181 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Initiated | William Blair | Outperform |
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
View All
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Eupraxia Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesDebt Analysis Report - newsline.com
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart
Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders - The Globe and Mail
Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K - TipRanks
Eupraxia (EPRX) details 2026 virtual AGM, board nominees and pay plan - Stock Titan
Eupraxia Pharmaceuticals (EPRX) confirms mailing of proxy materials to holders - Stock Titan
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Revision Downgrade - The Legal Advocate
Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference - TipRanks
Eupraxia Pharmaceuticals (EPRX) to present at Jefferies Global Healthcare Conference - Stock Titan
(EPRX.WT.A) Equity Market Report - Stock Traders Daily
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - NorthBayNipissing.com
Biotech Eupraxia heads to New York for Jefferies health conference June 3 - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Rises 2.3% as Stock Approaches Key Resistance LevelDay Trade Opportunities - newsline.com
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Earnings: Clinical Progress Overshadows Slight EPS MissLong-Term Guidance - Newser
Stifel Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Miss: What Went WrongCommunity Exit Signals - Newser
Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target - Moomoo
This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Certain Non-Voting Class B Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Common Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating - Investing.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LifeSci Capital Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
William Blair Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating - Moomoo
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Manchester entities, Besser & Frank disclose EPRX holdings (EPRX) - Stock Titan
Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing - TipRanks
Eupraxia Pharmaceuticals: Well-capitalized Into 2H28 >EPRX.T - Moomoo
Eupraxia Pharmaceuticals reports first quarter 2026 financial results - marketscreener.com
Eupraxia Pharmaceuticals Q1 Loss Narrows - Moomoo
Eupraxia (NASDAQ: EPRX) funds EP-104GI trial despite higher quarterly loss - Stock Titan
Eupraxia Pharmaceuticals Says "Well-capitalized into Second Half 2028, Beyond Key Catalysts" With Over US$140M Cash - marketscreener.com
Eupraxia Pharmaceuticals Cites "Robust Response" In Highest Dose Cohort After 36 Weeks Following a Single Treatment of EP-104GI - marketscreener.com
Eupraxia Pharmaceuticals Incurred a Q1 Net Loss of US$12.7M - marketscreener.com
EPRX: Eupraxia Pharmaceuticals Inc.Interactive Chart - Zacks Investment Research
Aisling Capital Management LP's Eupraxia Pharmaceuticals Inc(EPRX) Holding History - GuruFocus
TradingKey - TradingKey
Number of shareholders of Eupraxia Pharmaceuticals, Inc. – FWB:X43 - TradingView
Eupraxia wins new (US) $15.50 target at Leede Financial - Cantech Letter
Eupraxia reports EoE trial data on inflammation and fibrosis By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Inc. - Menafn.com
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart.com
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia reports EoE trial data on inflammation and fibrosis - Investing.com UK
Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI - TipRanks
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - The Manila Times
In Eupraxia’s top-dose EoE cohort, tissue scores improved >90% - Stock Titan
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):